论文部分内容阅读
目的探讨用“固定剂量率”方法使用吉西他滨治疗恶性肿瘤的可行性。方法23例经病理或影像学资料证实的恶性肿瘤患者(NSCLC、NPC、经治复发乳腺癌及胰腺癌)接受GP方案化疗(其中吉西他滨采用“固定剂量率”方法滴注)3周重复,每名患者至少完成两周期化疗,并评价化疗毒副作用及疗效。结果共完成51周期化疗,所有患者均可进行疗效及毒副反应评价。总有效率:52.17%;获益率(CR+PR+SD):86.95%。毒性反应主要为血液学毒性,尤其Ⅲ/Ⅳ度血小板降低占31.4%(16/51)周期。结论在GP方案中采用固定剂量率滴注吉西他滨治疗中晚期NSCLC、鼻咽癌、经治复发乳腺癌及中晚期胰腺癌是可行的方法,具有较高有效率、临床受益率及临床受益反应率,其毒副作用可耐受,值得进一步研究,以探讨合适的吉西他滨用量。
Objective To explore the feasibility of using the “fixed dose rate” method for the treatment of malignant tumors with gemcitabine. Methods Twenty-three patients with malignancy (NSCLC, NPC, conventionally relapsed breast cancer and pancreatic cancer) confirmed by histopathology or imaging data were treated with GP regimen (gemcitabine was given by “fixed dose rate” method) for 3 weeks. Patients completed at least two cycles of chemotherapy, and evaluate the side effects of chemotherapy and efficacy. Results A total of 51 cycles of chemotherapy were completed, all patients can be evaluated for efficacy and toxicity. Total effective rate: 52.17%; rate of return (CR + PR + SD): 86.95%. Toxicity was mainly hematological toxicity, especially Ⅲ / Ⅳ thrombocytopenia accounted for 31.4% (16/51) cycles. Conclusion In the GP regimen, a fixed dose rate gemcitabine is a feasible way to treat advanced non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma, advanced breast cancer and advanced pancreatic cancer. It has high efficiency, clinical benefit rate and clinical benefit response rate , Its toxic side effects are tolerable, it is worth further study to explore the appropriate amount of gemcitabine.